Literature DB >> 19085372

Major age group-specific differences in conjunctival bacteria and evolution of antimicrobial resistance revealed by laboratory data surveillance.

Nina Hautala1, Markku Koskela, Timo Hautala.   

Abstract

PURPOSE: We hypothesized that observation and analysis of microbiological laboratory statistics from patients with suspected bacterial conjunctivitis should increase our understanding of microbiological epidemiology of the disease in age categories. We further assumed that the statistical data should expose evolution of antimicrobial resistance that may eventually have an influence on clinical decisions.
MATERIALS AND METHODS: We analyzed statistical data of bacterial isolates (1139 strains) and their resistance to common antibiotics from 2494 patients with suspected bacterial conjunctivitis.
RESULTS: Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus displayed their presence in 0- to 5-year-old children. Staphylococcus aureus and Pseudomonas aeruginosa were the most common in the elderly (>age 70) among whom a rapid increase in resistance of Staphylococcus aureus to methicillin (MRSA) was recognized.
CONCLUSIONS: Our study demonstrates that the spectrum of conjunctival bacteria varies among age groups. In addition, our results confirm that a shift in antimicrobial susceptibility can be rapid and age-group specific, thus emphasizing the need for continuous surveillance of bacterial findings.

Entities:  

Mesh:

Year:  2008        PMID: 19085372     DOI: 10.1080/02713680802475338

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  6 in total

1.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Authors:  Adebukola Adebayo; Jignesh G Parikh; Steven A McCormick; Mahendra K Shah; Remedios S Huerto; Guopei Yu; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

2.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.

Authors:  Wolfgang Haas; Lynne S Gearinger; Dale W Usner; Heleen H Decory; Timothy W Morris
Journal:  Clin Ophthalmol       Date:  2011-09-21

4.  Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis.

Authors:  Tanweer S Zaidi; Tauqeer Zaidi; Gerald B Pier
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-05-01       Impact factor: 4.799

Review 5.  A Pyrrhic Victory: The PMN Response to Ocular Bacterial Infections.

Authors:  Erin T Livingston; Md Huzzatul Mursalin; Michelle C Callegan
Journal:  Microorganisms       Date:  2019-11-07

6.  The Effect of Topical Ocular Anesthetic Proparacaine on Conjunctival and Nasal Mucosal Flora in Dry Eye Disease Patients.

Authors:  Ozlem Onerci Celebi; Ali Riza Cenk Celebi
Journal:  J Clin Med       Date:  2018-04-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.